Article · 5 Oct 2026
Research articlePublished 5 Oct 2023
An Open Label, Balanced, Randomized, Two Treatments, Two Sequences, Two Periods, Crossover, Single Dose, Oral Bioequivalence Study of Femelle 20 (Drospirenone 3 Mg and Ethinyl Estradiol 0.02 Mg) Coated Tablets of Abbott and Yaz® (Drospirenone 3 Mg And Ethinyl Estradiol 0.02 Mg) Coated Tablets of Bayer in Healthy, Adult, Human Female Subjects Under Fasting Condition
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Yaz® Drospirenone and ethinyl estradiol is a Combined Oral Contraceptive (COC). Drospirenone is a spironolactone analogue with anti-mineralocorticoid and anti-androgenic activity. The estrogen in Yaz® is ethinyl estradiol. COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Yaz® is also indicated for the treatment of symptoms of Pre Menstrual Dysphoric Disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception. The purpose of this study was to evaluate the bioequivalence between Femelle 20 (Drospirenone 3 mg and ethinyl estradiol 0.02 mg) coated tablets of Abbott versus Yaz® (Drospirenone 3 mg and ethinyl estradiol 0.02 mg) coated tablets of Bayer under fasting condition in healthy non-pregnant female subjects. An open label, balanced, randomized, two treatments, two sequences, two periods, crossover, single dose study with washout period of 14 days was carried out in 36 healthy non-pregnant female subjects in the age group of 22 to 42 years, who met the study eligibility criteria, participated in the study and all 36 subjects completed both the periods of the study. The pharmacokinetic samples collected from subjects who completed the study were analyzed to determine the plasma concentration of Drospirenone and ethinyl estradiol using a validated bio-analytical method. Ninety percent confidence interval of Cmax and AUC0-72 were 100.45%-119.63% and 98.04%-104.50%, respectively for Drospirenone and 90% confidence interval of Cmax, AUC0-t and AUC0-∞ were 93.76%-102.39%, 102.42%-110.02% and 101.37%-108.84%, respectively for ethinyl estradiol, which were within the acceptable limits of 80.00% to 125.00%.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Arjun Arumugam O”
- BylineArticles whose byline prints “Geethalakshmi G”
- BylineArticles whose byline prints “Srinivas G”
- BylineArticles whose byline prints “Kramm Karina”
- BylineArticles whose byline prints “Sasso Jaime”
- BylineArticles whose byline prints “Vergara Sebastian”
- BylineArticles whose byline prints “Ghünter Erich”
- BylineArticles whose byline prints “Salazar Boris”